Posted by Michael Wonder on 11 Dec 2020
Pfizer and BioNTech receive FDA Advisory Committee vote supporting potential first emergency use authorisation for vaccine to combat COVID-19 in the U.S
10 December 2020 - FDA expected to make a decision on Emergency Use Authorization in the coming days.
Pfizer and BioNTech announced today that the U.S. FDA Vaccines and Related Biological Products Advisory Committee voted 17 to 4 in support of the FDA granting emergency use authorisation for the companies’ COVID-19 mRNA vaccine (BNT162b2).
There is one member of the Committee whose vote is not included in the 17 to 4 vote decision.
